Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Bionical Emas sells EMAS Pharma to Kester Capital following strategic review
-
Kester Capital backs experienced management team in acquiring EMAS Pharma
-
Moma update
-
Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders
-
Vow ASA: Last day of the subscription period in the rights issue
-
Transaction in Own Shares
-
Subsea7 share repurchases
-
KFSHRC Leads Innovation in Cancer Radiopharmaceuticals
-
New Final Bond Terms for Nykredit Realkredit A/S's Base Prospectus dated 8 May 2024 - Nykredit Realkredit A/S
-
Lleida.net's monthly turnover customers over 5,000 euros per month increase 38.6% in the period from November 2023 to November 2024
-
Havila Shipping ASA: Financing update and invitation to fixed income investor meetings
-
Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement
-
Bayport Management Ltd updates the prospective record date and exchange date for the exchange of its outstanding senior and subordinated social bonds.
-
Jetex announced as the exclusive operator of Red Sea International Airport's Private Jet Terminal
-
Vastned Belgium has obtained commitments for the financing of EUR 345 million subject to completion of the reverse cross-border merger
-
Start of Day Message
-
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function
-
Arcadis completes share buyback program and reports final transactions
-
Announcement on the first results of EfTEN Real Estate Fund AS public share offering
-
Trym Reboot Boosts North Sea Output
-
China Medical System: First Prescriptions for Innovative Drug Lumeblue® Issued in China
-
Pozalabs Responds to SACEM, Addresses Ethical AI Music Generation Concerns
-
Francisco Velasquez AgriCarm Unveils App to Empower Farmers
-
BeautyRightBack Launches New Subscription Service for Beauty Services
-
Aura Minerals Announces Positive Exploration Results from Multiple High-Potential Projects
-
Lead Real Estate Co., Ltd. Opening New Apartment Hotel, ENT TERRACE GINZA PREMIUM, in Tokyo
-
Zelixir's New Factory to Revolutionize Natural Fragrance Production with ‘AI+Synthetic Biology’
-
Zelixir's New Factory to Revolutionize Natural Fragrance Production with ‘AI+Synthetic Biology’
-
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeti
-
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at Americ
-
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
-
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
-
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
-
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
-
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
-
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
-
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
-
CWTI Provides Revised Update on Canada Postal Strike Delay Mailing of the Company's 2024 Annual General Meeting Materials
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leuke
-
EliteSignals Unveils Revolutionary Forex Trading Bot: EliteX
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
-
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
-
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
-
Caribbean Airlines Brings the Region Closer with New Service to Guadeloupe
-
Pennsylvania Skill, powered by Pace-O-Matic, Responds to Commonwealth Court Ruling in Favor of Skill Games
-
HII Christens Virginia-Class Attack Submarine Arkansas (SSN 800)
-
Admirals Group AS Announces a Sale of its Australian Subsidiary
-
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
-
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
-
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
